A randomized controlled  pilot trial of anakinra for hemodialysis inflammation

Chronic inflammation is highly prevalent among patients receiving maintenance hemodialysis and is associated with morbidity and mortality. Inhibiting inflammation with anti-cytokine therapy has been proposed but not well studied in this population. Therefore, we conducted the ACTION trial, a pilot, multicenter, randomized, placebo-controlled trial of an IL-1 receptor antagonist, anakinra, to evaluate safety, tolerability, and feasibility, and explore efficacy. Eighty hemodialysis patients with plasma concentrations of high sensitivity C-reactive protein (hsCRP) 2 mg/L and above were randomized 1:1 to placebo or anakinra 100 mg, three times per week via the hemodialysis circuit for 24 weeks, with an additional 24 weeks of post-treatment safety monitoring.

Source: Kidney International - July 18, 2022 Category: Urology & Nephrology Authors: Laura M. Dember, Adriana Hung, Rajnish Mehrotra, Jesse Y. Hsu, Dominic S. Raj, David M. Charytan, Finnian R. Mc Causland, Renu Regunathan-Shenk, J. Richard Landis, Paul L. Kimmel, Alan S. Kliger, Jonathan Himmelfarb, T. Alp Ikizler, Hemodialysis Novel The Tags: clinical trial Source Type: research